AI English summary of an SEC filing — figures as filed

Abbott said on December 12, 2025 that Nita Ahuja, M.D. was named to Abbott Laboratories' Board of Directors.

8-KDeparture or Appointment of Directors or Certain OfficersFiled Dec 12, 2025Period of report Dec 12, 2025Summary published (UTC) Oct 12, 2026

Key points

AI summary

Abbott said on December 12, 2025 that Nita Ahuja, M.D. was named to Abbott Laboratories' Board of Directors.
Abbott said on December 12, 2025 its Board of Directors amended the first sentence of Article III, Section 2 of its by-laws to provide that the Board of Directors shall consist of 13 persons, effective as of that date.
Abbott said its by-laws previously provided that the Board of Directors consisted of 12 persons.
The company said it filed as Exhibit 99.1 the By-Laws of Abbott Laboratories, as amended and restated, effective December 12, 2025.

Summary

AI-written

Analysis scope · Filing body only (exhibits excluded)We analyzed the filing body only. The exhibits exceeded the length limit and were excluded, so figures, financial statements and presentation materials in them were not reviewed.

Nita Ahuja, M.D. Named to Board of Directors

Abbott said on December 12, 2025 that Nita Ahuja, M.D. was named to Abbott Laboratories' Board of Directors.

Source · Based on the filing body (exhibits excluded)

Board of Directors size changed from 12 to 13 persons

Abbott said on December 12, 2025 its Board of Directors amended the first sentence of Article III, Section 2 of its by-laws to provide that the Board of Directors shall consist of 13 persons, effective as of that date.

Source · Based on the filing body (exhibits excluded)

Previous by-laws provision on number of directors

Abbott said its by-laws previously provided that the Board of Directors consisted of 12 persons.

Source · Based on the filing body (exhibits excluded)

Amended and Restated By-Laws Filed

The company said it filed as Exhibit 99.1 the By-Laws of Abbott Laboratories, as amended and restated, effective December 12, 2025.

Source · Based on the filing body (exhibits excluded)

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.